Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results.

Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results.

Busch C, Fraser-Bell S, Iglicki M, Lupidi M, Couturier A, Chaikitmongkol V, Giancipoli E, Rodríguez-Valdés PJ, Gabrielle PH, Laíns I, Santos AR, Cebeci Z, Amphornphruet A, Degenhardt V, Unterlauft JD, Cagini C, Mané-Tauty V, D’Amico Ricci G, Hindi I, Agrawal K, Chhablani J, Loewenstein A, Zur D, Rehak M; International Retina Group.

Acta Diabetol. 2019 Dec;56(12):1341-1350. doi: 10.1007/s00592-019-01416-4. Epub 2019 Sep 21.

2019

Serum pro-inflammatory factors as predictors of persistent diabetic macular oedema with limited anatomic response to anti-VEGF: association with intravitreal injection treatment profiles in real-world setting.

Serum pro-inflammatory factors as predictors of persistent diabetic macular oedema with limited anatomic response to anti-VEGF: association with intravitreal injection treatment profiles in real-world setting.

Brito P, Costa J, Gomes N, Costa S, Correia-Pinto J, Silva R.

Acta Ophthalmol. 2019 Nov 19. doi: 10.1111/aos.14308. [Epub ahead of print]

MACUSTAR: Entwicklung und klinische Validierung von funktionellen, strukturellen und patientenberichteten Endpunkten bei intermediärer altersabhängiger Makuladegeneration

MACUSTAR: Entwicklung und klinische Validierung von funktionellen, strukturellen und patientenberichteten Endpunkten bei intermediärer altersabhängiger Makuladegeneration

Jan H. Terheyden, Robert P. Finger, Steffen Schmitz-Valckenberg,
Hansjürgen Agostini, ClaudiaDahlke, Laura Kuehlewein, Gabriele E. Lang,
Daniel Pauleikhoff, ArminWolf, Michael K. Boettger, Ulrich F. O. Luhmann,
Friedrich Asmus, Frank G. Holz, für MACUSTAR-Konsortium

Der Ophthalmologe, doi:10.1007/s00347-019-0907-1

2019